Fcγ-receptor-IIIA bioactivity of circulating and synovial immune complexes in rheumatoid arthritis
Authors' conclusion
RA is characterised by the presence of circulating and synovial sICs that can engage and activate CD16.
Study context
- Population
- Patients with rheumatoid arthritis (RA) and control diseases (PsA, systemic lupus erythematosus (SLE)) and healthy controls; sera and synovial fluid26 synovial fluid samples
- Participants
- 50 / 106 / 20 / 22 / 31
- Comparison
- RA vs PsA, SLE and healthy controls
- RA (exploratory)n = 50
- RA (validation)n = 106
- PsAn = 20
- SLEn = 22
- Healthy controlsn = 31reference
- Outcome
- Presence of CD16-activating sICs
Methodological detailsexploratory cohort, validation cohort, reporter cell assay
- Exploratory cohort
- Validation cohort
- Reporter cell assay
Main finding
As reported in the abstract
CD16-activating sICs
- Presence of soluble immune complexes (sICs) in RA sera confirmed; sICs activate CD16, found in synovial fluid and blood
- Circulating sICs also detected in low dilutions in a subset of healthy people and in PsA
- Significantly increased frequency of bioactive circulating sICs in RA
- Circulating sICs bioactivity low, not correlated with clinical parameters; synovial sICs highly bioactive, correlated with serum autoantibody levels
- ROC: synovial sICs bioactivity could discriminate immune complex-associated arthritis from non-associated forms
- Circulating sICs more frequent in SLE than in RA
- CD16 bioactivity showed strong donor-dependent differences, especially in SLE
Original publication
Fcγ-receptor-IIIA bioactivity of circulating and synovial immune complexes in rheumatoid arthritis. RMD Open. Published 28 August 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →